Published in Trends Pharmacol Sci on June 01, 2002
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci U S A (2002) 4.52
SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med (2012) 4.27
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A (2004) 3.73
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol (2006) 3.57
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem (2004) 3.56
Complementary function of the two catalytic domains of APOBEC3G. Virology (2005) 3.45
Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci U S A (2003) 2.71
HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci U S A (2007) 2.50
Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol (2005) 2.17
Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx. J Virol (2009) 1.91
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells. J Virol (2011) 1.85
CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature (2012) 1.85
Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem (2002) 1.79
Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol (2006) 1.69
Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog (2009) 1.65
Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology (2009) 1.50
The Vpx lentiviral accessory protein targets SAMHD1 for degradation in the nucleus. J Virol (2012) 1.47
The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses (2003) 1.40
Recent insights into HIV-1 Vif. Curr Opin Immunol (2004) 1.30
Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J Biol Chem (2006) 1.30
Restriction of diverse retroviruses by SAMHD1. Retrovirology (2013) 1.23
Chimeric human immunodeficiency virus type 1 containing murine leukemia virus matrix assembles in murine cells. J Virol (2002) 1.15
The cargo-binding domain of transportin 3 is required for lentivirus nuclear import. J Virol (2011) 1.09
Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology (2004) 1.06
HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest. Virology (2003) 1.00
Accessories to the crime: recent advances in HIV accessory protein biology. Curr HIV/AIDS Rep (2009) 0.96
New insights into the role of Vif in HIV-1 replication. AIDS Rev (2004) 0.95
HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx. AIDS Res Hum Retroviruses (2013) 0.94
Inhibition of CUL4A Neddylation causes a reversible block to SAMHD1-mediated restriction of HIV-1. J Virol (2013) 0.92
Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii. Blood (2003) 0.91
Vpr- and Nef-dependent induction of RANTES/CCL5 in microglial cells. Virology (2002) 0.88
Analysis of Vif-induced APOBEC3G degradation using an alpha-complementation assay. Virology (2006) 0.81
Interactions with DCAF1 and DDB1 in the CRL4 E3 ubiquitin ligase are required for Vpr-mediated G2 arrest. Virol J (2014) 0.78
Production and use of HIV-1 luciferase reporter viruses. Curr Protoc Pharmacol (2003) 0.76
SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies. bioRxiv (2022) 0.75